CCND1 G870A polymorphism and cervical cancer risk: a case-control study and meta-analysis

J Cancer Res Clin Oncol. 2011 Mar;137(3):489-94. doi: 10.1007/s00432-010-0904-x. Epub 2010 May 15.

Abstract

Purpose: Cyclin D1 (CCND1) is a key regulatory protein in the G1/S checkpoint of the cell cycle. We hypothesized that the G870A polymorphism of CCND1 is associated with the risk for cervical cancer and performed a meta-analysis of eligible studies to evaluate this relationship.

Methods: In a case-control study of 300 patients with newly diagnosed cervical cancer and 312 cancer-free controls who were frequency-matched by age, we genotyped the G870A polymorphism of CCND1 by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). A meta-analysis was performed using five case-control studies, including our results.

Results: No significant association was observed between the G870A polymorphism of CCND1 and cervical cancer risk. Further, in our meta-analysis, there was no significant risk of cervical cancer that correlated with the G870A polymorphism of CCND1. In the stratified analysis by race, however, individuals who harbored the AA or AA/AG genotypes were at significantly greater risk compared with GG carriers in the Asian population.

Conclusion: The G870A polymorphism in CCND1 may not contribute to the etiology of cervical cancer in Chinese populations.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Case-Control Studies
  • Cyclin D1 / genetics*
  • Female
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • Middle Aged
  • Polymerase Chain Reaction
  • Polymorphism, Restriction Fragment Length
  • Polymorphism, Single Nucleotide
  • Uterine Cervical Neoplasms / genetics*

Substances

  • CCND1 protein, human
  • Cyclin D1